News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade/hiranandanihospital.org
Apr 16, 2025, 17:55

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:

“LET’S PLAY DEVIL’S ADVOCATE:

Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –

Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.

I broke it down—with counterarguments .

Do Check this out.”

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor

Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo 

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

More posts featuring Amol Akhade.

Amol Akhade Breast Cancer cancer cancer treatment Ian F. Tannock OncoDaily Oncology Qamar J. Khan Tito Fojo
Special Coverage
Blog
May 9, 2025, 11:11
Jessie Dalman: Proud of Emily Barrett for Finishing Her Time as a Chief Resident
Opinion
May 9, 2025, 11:07
Bold Leadership and Vision: Why Dr. Narjust Florez Deserves Undesignated IASLC Board Seat #4 - Florez Lab
Blog
May 9, 2025, 11:01
Runcie C.W. Chidebe: Join Our Team at Devatop Centre for Africa Development
Blog
May 9, 2025, 10:56
City Cancer Challenge Expands Technical Partnerships to Strengthen Global Cancer Care
Opinion
May 9, 2025, 10:55
Jay Bhattacharya Halts NIH Lab Operations Over Biocontainment Breach
Blog
May 9, 2025, 10:50
Maria (Masha) Babak: Honored to Receive the College of Science Teaching Excellence Award
Blog
May 9, 2025, 10:42
BSMO Highlights Need for Sustainable Support in Belgium’s Precision Oncology Efforts
Blog
May 9, 2025, 10:37
Yuji Uehara: Thrilled to Receive a Travel Grant for ESMO TAT Asia25
Blog
May 9, 2025, 10:32
Julie Torode Believes That Collaboration Is Key to Ending Global Ovarian Cancer Inequities - World Ovarian Cancer Coalition
Blog
May 9, 2025, 10:29
Cathy Eng: Polyps Removed, so Back Again in 3 years
Blog
May 9, 2025, 10:15
Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer
Blog
May 9, 2025, 10:04
Aakash Desai: AI in Predicting EGFR Mutations from Whole Slide Images in Lung Cancer